AMONDYS 45 Drug Patent Profile

When do Amondys 45 patents expire, and what generic alternatives are available?

Amondys 45 is a drug marketed by Sarepta Theraps Inc and is included in one NDA. There are five patents protecting this drug.

This drug has eighty-eight patent family members in twenty-five countries.

The generic ingredient in AMONDYS 45 is casimersen. One supplier is listed for this compound. Additional details are available on the casimersen profile page.

DrugPatentWatch^® Generic Entry Outlook for Amondys 45

Amondys 45 was eligible for patent challenges on February 25, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 25, 2028. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for AMONDYS 45

International Patents:	88
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AMONDYS 45
What excipients (inactive ingredients) are in AMONDYS 45?	AMONDYS 45 excipients list
DailyMed Link:	AMONDYS 45 at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for AMONDYS 45

Constraining patent/regulatory exclusivity:

TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING

NDA:

213026

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for AMONDYS 45

Drug Class	Antisense Oligonucleotide
Physiological Effect	Increased Protein Synthesis

US Patents and Regulatory Information for AMONDYS 45

AMONDYS 45 is protected by seven US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021		RX	Yes	Yes
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021		RX	Yes	Yes			Y	Y
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021		RX	Yes	Yes			Y	Y

Expired US Patents for AMONDYS 45

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021

International Patents for AMONDYS 45

See the table below for patents covering AMONDYS 45 around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2010317599
Australia	2016202924
Australia	2018202105

Last updated: June 9, 2026

AMONDYS 45 (casimersen) market dynamics and financial trajectory: sales, reimbursement, exclusivity, and competitive threats

AMONDYS 45 (casimersen) is a Duchenne muscular dystrophy (DMD) exon-skipping therapy for patients with confirmed mutation amenable to exon 45 skipping. Commercial performance is constrained by narrow genotype eligibility, premium pricing with payer friction, and intensifying competitive pressure from alternative exon-skipping agents and disease-modifying entrants that target overlapping DMD subpopulations. Financial trajectory is dominated by: (1) the size of the exon 45-skipping treatable population, (2) access and coverage decisions by specialty pharmacy and payer formularies, and (3) life-cycle events around patent and regulatory exclusivity, including potential generics/biosimilar risk (unlikely for a peptide/oligonucleotide like casimersen), offset by method-of-action and formulation IP barriers.

---

What drives AMONDYS 45 sales growth and pricing power in Duchenne muscular dystrophy?

Primary demand drivers

• Eligible patient identification: AMONDYS 45 is used only in patients with mutations amenable to exon 45 skipping in DMD.
• Genetic testing penetration: Higher uptake of DMD genetic testing expands the addressable population and improves rate of diagnosis-to-treatment conversion.
• Payer acceptance of exon-skipping class: In the exon-skipping segment, payers increasingly evaluate evidence, dosing frequency, and total annual treatment cost. Prior acceptance of similar therapies reduces friction for follow-on therapies, but payer scrutiny stays high for high-cost drugs.

Economic levers

• Specialty pharmacy and infusion logistics: Casimersen is administered by IV infusion. Cold-chain handling and infusion capacity influence provider uptake and patient adherence.
• Reimbursement structure: Commercial coverage is typically mediated through specialty pharmacy arrangements and prior authorization, with copay support used to maintain net-to-patient accessibility.
• Net price vs list price: High list pricing often translates into lower realized net revenue after rebates, discounts, and patient assistance programs.

Market comparison context Within DMD, payer and provider decision-making typically prioritizes:

• Genotype fit (which exon is skippable),
• Clinical endpoints and durability of dystrophin expression versus historical benchmarks,
• Practical administration and monitoring burden,
• Total cost and coverage policies relative to alternatives.

---

How big is the AMONDYS 45 addressable market based on exon 45 skipping prevalence?

Sizing logic used by payers and manufacturers

1. Total incident/prevalent DMD population in the U.S. and major EU markets.
2. Share with mutations amenable to exon 45 skipping.
3. Share with confirmed genotype via standardized sequencing/assay pathways.
4. Treatment initiation rate among eligible patients.
5. Switching and persistence across exon-skipping therapies and supportive care landscapes.

Commercial implication Even with strong payer coverage, exon 45 eligibility is the hard cap. If exon 45 skipping represents a smaller fraction of DMD genotypes relative to other exons (common patterns include exons 51, 53, and 44 depending on cohort), AMONDYS 45 revenue ceiling is structurally lower than therapies addressing a larger genotypic slice.

---

What is AMONDYS 45 revenue trajectory since launch, and how does it reflect adoption constraints?

Trajectory characteristics common to genotype-limited DMD therapies

• Launch ramp is slow when:
  • diagnosis rates and sequencing coverage are uneven,
  • payers require stringent documentation for eligibility,
  • clinicians need time to build patient flow and infusion workflow.
• Revenue grows with testing penetration rather than broad indication expansion.
• Revenue plateau risk increases when:
  • the remaining untreated eligible pool shrinks,
  • competitors pull switching share (for overlapping or adjacent genotype segments),
  • payer policies tighten due to budget impact.

What financial reporting typically shows in this segment For exon-skipping therapies, revenue curves often correlate with:

• Specialty pharmacy distribution scale-up,
• Coverage determinations and evidence submission strength,
• Evidence maturity at renewal cycles for institutional contracts.

Competitive effect If another exon-skipping or dystrophin-restoring therapy becomes preferred on coverage terms, the total category budget can lead to share shifts even without a change in AMONDYS 45 eligibility.

---

What exclusivity protects AMONDYS 45, and when does it lose exclusivity?

AMONDYS 45 is a prescription biologic/oligonucleotide therapy with multiple layers of IP and regulatory exclusivity (data exclusivity, possible marketing authorization exclusivity, and patent coverage across active, processes, and formulations). The commercial timeline is therefore shaped by:

• Patent expiration dates (compound and downstream claims),
• Regulatory exclusivity that blocks relying on certain data packages for a period after approval,
• Orphan drug exclusivity where applicable (often relevant for rare disease),
• Payer substitution rules and clinical practice patterns that persist even after formal barriers diminish.

Commercial risk profile

• For oligonucleotide drugs, direct generic substitution is not straightforward, so the main threat typically comes from competing brand therapies and follow-on IP workarounds, not immediate chemical “generic” entry.

---

What patents protect AMONDYS 45 (casimersen), and how strong is the estate for blocking copycats?

AMONDYS 45’s market durability depends on the scope and expiration of:

• Sequence-specific composition-of-matter patents covering the casimersen oligonucleotide,
• Formulation and delivery patents (stability, excipients, manufacturing process),
• Manufacturing process patents (synthetic routes, purification, quality control).

Estate strength is judged by

• how broadly claims cover modifications,
• how many independent claim families remain in force across key jurisdictions,
• and whether litigation has narrowed scope.

Why that matters commercially If downstream claims remain intact, competitors can only pursue:

• different exon-skipping targets,
• different chemical chemistries or conjugation strategies,
• or fully licensed alternatives with separate IP clearance.

---

What FDA approval and labeling limits govern how AMONDYS 45 is marketed and prescribed?

Label constraints

• Mutation amenable to exon 45 skipping is the core qualifying criterion.
• Confirmed diagnosis and adherence to prescribing criteria affect utilization.

Practical impact Clinicians can face administrative friction for payers:

• prior authorization documentation,
• demonstration of exon 45 amenability,
• sometimes baseline dystrophin/clinical documentation.

This labeling-driven gatekeeping is a key determinant of near-term revenue ramp and payer churn resistance.

Regulatory access pathways AMONDYS 45 has an established regulatory standing, but future market expansion would require labeling expansion, trial evidence, or new manufacturing/clinical claims, each of which typically takes time and capital.

---

What generic entry risks exist for AMONDYS 45, and is a Paragraph IV challenge realistic?

Realistic entry pathways

• For casimersen, the primary competitive threat is new brand exon-skipping therapies and different molecular approaches aimed at dystrophin restoration.
• A Paragraph IV strategy depends on whether an approved reference-bridge pathway exists for a similar product and whether the regulatory framework treats the candidate as substitutable in a way that supports a legal challenge.

Commercial conclusion Even where legal mechanisms exist, the combination of:

• complex oligonucleotide characterization,
• manufacturing controls,
• and layered IP claims makes immediate generic-like entry an unlikely driver of near-term revenue collapse compared with competitive brand dynamics.

---

How does AMONDYS 45 compete versus other DMD exon-skipping drugs and dystrophin-restoring therapies?

Competitive set AMONDYS 45 competes in DMD with other exon-skipping options that target different exons and can overlap with patient genotypes depending on mutation profiles and eligibility criteria.

Competition vectors

• Coverage preference: Some payers establish preferred exon targets or contract-based rankings.
• Patient switching: In practice, switching occurs when clinicians view another therapy as more aligned to patient genotype, with a favorable access path.
• Budget impact management: Large centers bargain across the category based on total cost.

Net effect on AMONDYS 45

• Revenue share tends to be stable within its exon-specific niche but can decline if:
  • payers tighten criteria for AMONDYS 45 continuation,
  • clinicians shift to competing therapies where eligible patients also match multiple exon amenability patterns (less common, but possible in certain genetic contexts),
  • or if alternative approaches demonstrate stronger functional outcomes.

---

What patent litigation and settlements affect AMONDYS 45 market exclusivity risk?

Litigation risk for AMONDYS 45 would typically arise from:

• challenges to specific patent families,
• disputes around claim scope for composition, formulation, and process patents,
• and any settlement that accelerates entry or permits market access for a contested product.

Commercial impact mechanism

• A settlement can change the expected exclusivity horizon by authorizing entry “at risk” or enabling an earlier launch date.
• Without litigation, exclusivity risk is primarily timeline-based from expiration and regulatory constraints.

---

How do payers, specialty pharmacies, and centers of excellence shape AMONDYS 45 adoption and persistence?

Payer levers

• Prior authorization and documentation requirements for exon 45 amenability.
• Step therapy practices are less common in rare-genotype indications but coverage policies still gate access.
• Renewal criteria can be tied to:
  • confirmed compliance,
  • tolerability,
  • and supportive clinical monitoring.

Provider behavior

• Centers with established neuromuscular programs are more likely to adopt fast if patient flow and infusion protocols exist.
• Treatment persistence depends on logistical capacity and perceived clinical value.

Net financial effect Persistence drives revenue more than new starts after the initial ramp period. If payer renewals become more stringent, discontinuation risk rises, lowering net revenue.

---

What is the AMONDYS 45 commercial outlook: base case, downside case, and upside case?

Base case

• Revenue remains tied to the steady availability of genetically confirmed exon 45-skipping patients and stable payer coverage.
• Growth depends on incremental diagnosis and stable persistence rather than label expansion.

Downside case

• Competitive share loss to alternate exon-skipping therapies or emerging approaches reduces starts.
• Payers tighten continuation criteria and demand additional evidence.
• Contract pricing dynamics reduce net revenue.

Upside case

• Higher testing coverage and improved care pathways increase eligible identification.
• Institutional formulary acceptance improves after evidence maturation and real-world experience.
• Patient persistence remains strong and discontinuation stays low.

---

Key Takeaways

• AMONDYS 45 revenue trajectory is governed by exon 45 genotype eligibility and payer access rules, not broad indication expansion.
• Market dynamics favor therapies with larger and more easily identifiable treatable populations; AMONDYS 45’s ceiling is structurally limited by mutation amenability.
• Competitive risk comes primarily from other DMD dystrophin-restoring and exon-skipping therapies through coverage preference and switching, not from rapid generic substitution.
• Financial performance is most sensitive to net pricing and persistence driven by prior authorization and renewal criteria.
• Exclusivity and patent estate strength determine downside timing, but near-term revenue volatility is more likely to be driven by payer and competitive dynamics than by generic entry.

---

FAQs

1. How do payers determine eligibility for AMONDYS 45 exon 45 skipping therapy?
2. What factors influence patient persistence on AMONDYS 45 after initiation?
3. Which DMD exon-skipping therapies most directly compete with AMONDYS 45 by payer coverage and patient genotype overlap?
4. What contract and specialty pharmacy mechanisms most affect AMONDYS 45 net revenue versus list price?
5. What exclusivity and patent-expiration timelines most influence the long-term sales horizon for casimersen?

---

References

No sources were provided or cited in the prompt.